Wegovy vs Zepbound: which works better, and for whom

TLDR. Zepbound at 15 mg shows higher mean weight loss than Wegovy at 2.4 mg in their separate registration trials (22.5 percent versus 14.9 percent), but the trials were not direct head-to-head. The SURMOUNT-5 head-to-head trial completed in late 2024 confirmed tirzepatide superiority in obesity. For some patients, Wegovy is the better pick: lower starting dose, single-injector pen design, broader insurance coverage in 2026, and cardiovascular outcomes data (SELECT) that tirzepatide does not yet match. Side-effect profiles differ slightly. The right drug depends on coverage, dose tolerance, and which side effects you can live with.

Wegovy and Zepbound dominate the FDA-approved GLP-1 weight loss market. Both work. Both are weekly injections. Both cost roughly the same on cash-pay through the manufacturer DTC channels. The question patients ask us most often is: which one will work better for me?

The honest answer: the registration-trial data favors Zepbound by a meaningful margin, but trial efficacy is not the only thing that matters. Coverage, side effects, dose flexibility and which program prescribes which all change the calculation. Here is the breakdown.

Trial efficacy: Zepbound has the higher headline number

Wegovy (semaglutide 2.4 mg) was studied in STEP-1, a 68-week trial. Mean weight loss at maximum tolerated dose was 14.9%, with 86.4% of patients losing at least 5% of body weight and 50.5% losing at least 15%.

Zepbound (tirzepatide 15 mg) was studied in SURMOUNT-1, a 72-week trial. Mean weight loss at the highest dose was 22.5%, with 91% of patients losing at least 5% and 57% losing at least 20%.

The gap is roughly 7-8 percentage points of mean body-weight loss, with Zepbound responder rates higher across every threshold. That is a real efficacy difference, larger than anything else in the GLP-1 class.

Why the trial gap may overstate the real-world gap

Three caveats worth holding in mind before treating SURMOUNT-1's 22.5% as a guarantee:

• Adherence in trials is higher than in life. Trial patients are paid to come back, have nurses calling them between visits and get medication delivered. Real-world adherence runs much lower, which compresses the gap.
• Maximum doses are not the same as tolerated doses. The headline numbers reflect patients on the highest dose. A substantial fraction in both trials stayed at lower doses due to GI side effects. Per-protocol versus intention-to-treat shifts the numbers.
• Both trials had similar dropout rates (roughly 13-17%). Patients who quit don't show up in the efficacy numbers. If you are the kind of patient who would quit, the trial means don't apply to you.

Side effects: similar profile, slight Zepbound edge on GI

Both drugs have the same boxed warning (thyroid C-cell tumors in rodent studies, not observed in humans). Both cause nausea, diarrhea, constipation, fatigue. Reading the trials side by side, Zepbound's GI-side-effect rates were a few percentage points lower than Wegovy's at comparable adherence, but the difference is small and many patients tolerate one and not the other for reasons that don't show up in averages.

The honest take: titrate slowly on either one. Don't compare yourself to the patient on Reddit who skipped from 0.25 mg to 2.4 mg in three weeks. They are not normal.

Cost: branded cash-pay has converged

Both manufacturers run DTC cash-pay programs that have pushed prices down hard since 2024. Wegovy through NovoCare is roughly $199-$499/month depending on dose. Zepbound through LillyDirect is roughly $349-$549/month depending on dose.

Compounded versions of both molecules exist through 503A pharmacies, typically $99-$249/month for semaglutide and somewhat higher for tirzepatide due to supply constraints. The regulatory environment around compounded tirzepatide has tightened in 2025-2026; check our compounded tirzepatide profile for the current state.

Insurance: Wegovy is more often covered

Among employer commercial plans, Wegovy coverage is more common than Zepbound coverage as of 2026, simply because Wegovy launched two years earlier and formulary committees moved slower on Zepbound. If you have an employer plan that covers GLP-1 weight loss, run the prior auth on Wegovy first and Zepbound second.

PlushCare, Form Health, and Knownwell are the programs in our chart that most actively run prior auth for branded GLP-1s.

If you have a clear preference

• If you have insurance that covers Wegovy: start with Wegovy. The copay path is usually $25-$50/month.
• If you have insurance that covers Zepbound (not Wegovy): start with Zepbound. The trial data supports it; coverage trumps theoretical efficacy.
• If you are cash-pay and want the highest mean weight loss: Zepbound, on the SURMOUNT-1 number.
• If you are cash-pay and price-sensitive: compounded semaglutide through a transparent 503A program like Mochi or Henry Meds.
• If you tried one and it did not work: switching to the other has higher success rates than you might expect. The molecules act on different receptors (semaglutide is GLP-1 only; tirzepatide is GLP-1 + GIP). Non-responders to one can respond to the other.

What we would actually do

If we were starting fresh in 2026, no insurance, cash-pay, mid-30s, BMI 32: start on compounded semaglutide at $150-$200/month for the first 6 months to establish tolerance and confirm meaningful weight loss. Then re-evaluate. If you respond well to semaglutide, stay there. If you plateau early or have lingering GI issues, switch to brand Zepbound through LillyDirect at $349-$549/month.

The wrong move is committing to brand Zepbound at $549/month before you know whether you tolerate the class.

See the full Wegovy vs Zepbound drug comparison for trial details, dosing schedules and side-effect tables.

Frequently asked questions

Is Zepbound really better than Wegovy?

On weight loss alone, yes, in the head-to-head SURMOUNT-5 trial. Zepbound 15 mg produced more weight loss than Wegovy 2.4 mg. The clinical comparison at equivalent dose strength is closer: Wegovy 2.4 mg is roughly equivalent to Zepbound 5 mg, both producing around 15 to 16 percent. The Zepbound advantage is the headroom: higher doses (10, 12.5, 15 mg) produce progressively more weight loss without a comparable Wegovy escalation option.

When would Wegovy be the better pick?

Three scenarios. First: established cardiovascular disease, where Wegovy has the SELECT trial 20 percent MACE reduction and Zepbound does not yet have a CVOT readout. Second: insurance covers Wegovy but not Zepbound on your plan. Third: severe GI side effects on tirzepatide that resolve on semaglutide (some patients tolerate one molecule better than the other).

Do Wegovy and Zepbound have different side effects?

Mostly the same: nausea, diarrhea, constipation, vomiting, fatigue. Nausea is slightly less common on tirzepatide than semaglutide at equivalent dose strength. Constipation and burping are slightly more common on tirzepatide. The pancreatitis and gallbladder signals are similar. Individual tolerance varies and a patient who cannot tolerate one molecule sometimes does fine on the other.

Is Wegovy or Zepbound cheaper?

Slightly different cash-pay floors. Wegovy through NovoCare starts at $149/mo introductory and $299 to $499/mo maintenance. Zepbound vials through LillyDirect start at $299/mo (5 mg) and rise to $549/mo (15 mg). With PA-approved commercial insurance, both land at $25 to $150/mo copay. The cheapest path depends on dose, insurance, and copay card eligibility.

Can I switch from Wegovy to Zepbound mid-treatment?

Yes, and it is a common move for patients who plateau on semaglutide. The typical protocol is to stop Wegovy and start Zepbound at 5 mg (not the lowest 2.5 mg, because the patient is GLP-1 experienced), then titrate up. Switching produces an additional 3 to 6 percent weight loss in plateaued semaglutide patients in real-world cohorts.